| Literature DB >> 27660450 |
Annemiek Dols1, Welmoed Krudop2, Christiane Möller2, Kenneth Shulman3, Martha Sajatovic4, Yolande Al Pijnenburg2.
Abstract
OBJECTIVES: Although bipolar disorder has been understood classically as a cyclic disease with full recovery between mood episodes, in the last decade, evidence has accumulated supporting progressive features. The clinical picture of advanced or end-stage bipolar disorder is heterogeneous with possible deficits in cognition and behavior, as illustrated by our case series. CASES: From our neuropsychiatric outpatient clinic, we describe four cases with bipolar disorder gradually developing a clinical syndrome, including apathy, disinhibition, loss of empathy, stereotypical behavior, and compulsiveness, fulfilling the criteria for possible behavioral variant frontotemporal dementia. All cases were diagnosed with bipolar 1 disorder at least 10 years before the onset of the current symptoms, which were not due to recent mood episodes or switches of medication. In all cases, 3-7 years of follow-up yielded no progression. Repeated neuroimaging was within normal limits. Cerebrospinal fluid biomarker studies were not supportive of underlying neurodegenerative pathology. C9orf72 mutation status was negative in all cases.Entities:
Keywords: benign phenocopy syndrome; bipolar disorder; bvFTD; older; staging
Year: 2016 PMID: 27660450 PMCID: PMC5019473 DOI: 10.2147/NDT.S99229
Source DB: PubMed Journal: Neuropsychiatr Dis Treat ISSN: 1176-6328 Impact factor: 2.570
Characteristics of the four cases
| Case 1 | Case 2 | Case 3 | Case 4 | |
|---|---|---|---|---|
| Age (years) | 78 | 70 | 65 | 62 |
| Sex | Male | Male | Male | Male |
| Education in years | 6 | 11 | 13 | 13 |
| Age at onset bipolar disorder (years) | 18 | 53 | 51 | 28 |
| Number of admissions | 3 | 1 | 2 | >2 |
| Family history (First degree) | Psychiatry | Cardiovascular | Cardiovascular | Cardiovascular |
| Somatic history | Diabetes | Myocardial infarction | Chronic obstructive pulmonary disease | Diabetes |
| Psychopharmaca | Lithium 800 mg | Lithium 1,200 mg | Quetiapine 400 mg | Lithium 800 mg |
| Disinhibition | + | + | + | + |
| Apathy | + | + | ||
| Loss of empathy | + | + | ||
| Stereotypical behavior | + | + | + | + |
| Eating behavior | + | + | ||
| Executive dysfunction | + | + | ||
| MMSE at presentation | 28 | 25 | 27 | 28 |
| MMSE after follow-up | 29 | 29 | 23 | 29 |
| FAB | 14 | 12 | 18 | 17 |
| FAB after follow-up | 12 | 17 | 15 | 18 |
| Mental speed/attention | Slightly decreased | Slightly decreased | Decreased | Normal |
| Executive tasks | Mildly disturbed | Mildly disturbed | Mildly disturbed | Normal |
| Episodic memory | Normal | Mildly disturbed | Normal | Normal |
| Semantic memory (category fluency) | Normal | Mildly disturbed | Normal | Normal |
| Visuospatial functions | Normal | Normal | Normal | Normal |
| Language | Normal | Normal | Normal | Normal |
| Social cognition profile (faux pas, Eckman faces) | n/a | Impaired, no recognition of faux pas, impaired recognition of disgust | Impaired, no recognition of faux pas, impaired recognition of sadness | Impaired recognition of sadness |
| MRI: Fazekas | 1 | 1 | 0 | 0 |
| MRI: MTA | 0/0 | 1/1 | 0/0 | 1/1 |
| MRI: GCA | 0 | 1 | Frontal 2, parietal 1, global 1 | 0 |
| FDG-PET | Normal | n/a | Normal | Normal |
| PIB-PET | n/a | n/a | Normal | n/a |
| CSF: amyloid beta-42 | 1,071 | 632 | n/a | 880 |
| (>550 pg/mL) | ||||
| CSF: tau (<375 pg/mL) | 400 | 202 | n/a | 486 |
| CSF: P-tau (<52 pg/mL) | 58 | 36 | n/a | 66 |
Abbreviations: CSF, cerebrospinal fluid; FAB, frontal assessment battery; FDG-PET, [18F]-2-deoxy-2-fluoro-d-glucose positron emission tomography; GCA, global cortical atrophy; MMSE, Mini-Mental State Examination; MRI, magnetic resonance imaging; MTA, medial temporal lobe atrophy; +, present; n/a, not applicable; PIB-PET, Pittsburgh compound B positron emission tomography; P-tau, phosphorylated tau.